Research Projects
XPRIME. Exploring and exploiting cross-priming in cancer immunotherapy
Researcher | Principal Investigator
Research Group on Dynamics of the antitumor immune response
Research Division
Cancer Division
Research program
Immunology and Immunotherapy
Research group
Dynamics of the antitumor immune response
Disease
Immunotherapy
Project information
XPRIME seeks to identify the dynamic roles of cDC1s in modulating CD8+ T cell responses during immunotherapy using acute depletion schemes, in vivo imaging techniques, and human cancer samples. We will study the role of PD-L1 expressed in this particular subset of dendritic cells as a potential target for immune checkpoint-based immunotherapy and define its limitations in antigen cross-priming. This is an R&D led by Dr Ýlvaro Teijeira, a researcher at the Immunology and Immunotherapy Program.
- Convocation: FIMA 2022 LAB AECC
- Reference: LABAE222982TEIJ
- Start date: December 1, 2022
- End date: November 30, 2025
- Funder: Asociación Española contra el Cáncer
- Nature of project: National
- Award year 2022
Need more information?
If you are interested in learning more about our research, please contact us.